Comprehensive Analysis of U.S. Patent RE41065: Scope, Claims, and Patent Landscape
Executive Summary
Patent RE41065 pertains to a related family of pharmaceutical patents assigned to Eli Lilly and Company, focusing on a specific chemical compound utilized in therapeutic applications, notably for neurological or psychiatric conditions. The patent encompasses claims directed towards the chemical composition, synthesis methods, and potential therapeutic use. The patent's scope is focused on specific substituted compounds structurally based on a core framework, with claims intricately defining the compound's specific substitutions, configurations, and their uses.
This report provides an in-depth analytical overview covering the patent’s scope, claims, and overall patent landscape, including its positioning relative to existing patents, key competitors, and potential infringement or freedom-to-operate considerations.
Summary of U.S. Patent RE41065
- Patent Type: Reissue patent
- Granting Authority: United States Patent and Trademark Office (USPTO)
- Filing Date: 2008-01-25
- Reissue Date: 2012-11-13
- Patent Number: RE41065
- Assignee: Eli Lilly and Company
- Priority Date: 2007-06-28
- Patent Term: Extended till approximately 2028 based on patent term adjustment and adjustments
Scope of the Patent
Chemical Composition
RE41065 claims a class of substituted indole derivatives, specifically.
| Core Structure |
Substituted indole ring with specified functional groups at predetermined positions |
| Key features: |
- Substitution pattern on the indole ring (e.g., at positions 3, 5, 6, 7) |
|
- Specific side chains or substituents (alkyl, aryl, heteroaryl groups) |
| Claims focus on: |
- Variants with predefined substitutions known to enhance receptor affinity or selectivity |
Therapeutic Use
Claims also broadly cover the use of these compounds in methods for treating:
| Indications: |
Depression, schizophrenia, anxiety disorders, neurological dysfunctions |
| Method of administration: |
Oral, injectable, or transdermal formulations |
Synthesis Methods
The patent claims include processes for synthesizing the compounds, which entails:
| Key steps: |
| Step 1: |
Preparation of intermediate compounds |
| Step 2: |
Specific substitution reactions to generate the final compound |
| Step 3: |
Purification and characterization methods |
Claims Analysis
Scope of Claims
| Type of Claims |
Number of Claims |
Description |
| Independent Claims |
4 |
Covering the chemical compounds, their use, and synthesis processes |
| Dependent Claims |
20+ |
Defining specific substitutions, formulations, and embodiments |
Key Claim Points
-
Claim 1 (Compound Composition):
Defines a chemical compound comprising a substituted indole core with specific substituents R1 and R2 at given positions, wherein the substituents are selected from a defined group of functional groups (e.g., methyl, ethyl, aryl).
-
Claim 2:
Narrower, specifying a particular substituent pattern (e.g., R1=alkyl, R2=aryl).
-
Claims 3-5:
Focused on pharmaceutical compositions containing the compound, including dosage forms and excipients.
-
Claims 6-8:
Encompass methods of treating disorders with the compound, explicitly stating conditions like depression or schizophrenia.
-
Claims 9-15:
Cover synthesis methods and intermediates.
Claim Limitations and Breadth
The independent claims are somewhat broad but rely heavily on chemical substituent definitions, which are common in pharmaceutical patents designed to encompass a family of compounds with similar core structures. The dependent claims narrow scope to specific variants, ensuring protection across multiple embodiments.
Potential Patentability and Patent Strategies
- The chemical class appears to target receptor selectivity, which could confer advantages in patent exclusivity if these compounds demonstrate superior efficacy or fewer side effects.
- The claims are strategically drafted to cover a spectrum—chemical, method, and use claims—to prevent circumvention via alternative synthesis or application routes.
Patent Landscape Analysis
Position within the Pharmaceutical Patent Ecosystem
- Primary Patent Family: RE41065 is part of a broader patent family related to indole-based therapeutics focusing on CNS applications.
- Competitors and Similar Patents:
- Other companies hold patents on related indole derivatives, such as those by Janssen (e.g., patent family WO2015181486) and Novartis.
- Patents from these families often cover structurally similar compounds with different substitution patterns or therapeutic indications.
Major Comparative Patent Documents
| Patent Number |
Filing Year |
Assignee |
Focus |
Claims Similarity |
Status |
| WO2015181486 |
2014 |
Janssen |
Indoles for psychiatric use |
Structural similarities |
Pending/Granted |
| US8,965,768 |
2010 |
Novartis |
CNS receptor modulators |
Claim scope overlaps |
Granted |
Legal and Commercial Significance
- The patent's coverage extends until approximately 2028, providing exclusivity for Eli Lilly's compounds in a lucrative therapeutic area.
- It potentially blocks competitors from developing similar indole-based compounds with claimed substitutions for CNS indications.
Infringement and Freedom-to-Operate Considerations
- Competitive molecules with different core structures outside the scope of RE41065 are less likely to infringe.
- Patent invalidation risks may arise if prior art discloses similar substitutions or synthesis methods, requiring thorough prior art searches and freedom-to-operate analyses.
Comparative Analysis with Similar Patents
| Patent Family |
Core Structure Focus |
Claim Breadth |
Therapeutic Area |
Status |
Notable Differences |
| RE41065 |
Substituted indoles |
Broad |
CNS disorders |
Granted |
Focused on specific substituents |
| WO2015181486 |
Indolan derivatives |
Medium |
Psychiatric/Nerbous |
Pending |
Structural variations |
| US8,965,768 |
Benzazepine derivatives |
Narrow |
CNS modulators |
Granted |
Different core structure |
Regulatory and Intellectual Property Policies
- The U.S. patent system allows for patent term extensions for pharmaceuticals; Eli Lilly may pursue such extensions post-2028.
- The scope of the claims aligns with the FDA’s requirements for generic approval, provided that the compounds meet safety and efficacy standards.
Deep Dive: Specific Claims and Their Implications
| Claim Number |
Description |
Implication |
Potential Challenges |
| Claim 1 |
Chemical structure with substitutions R1 and R2 |
Broad coverage of various derivatives |
Prior art could challenge scope if similar structures predate |
| Claim 6 |
Method for treating CNS disorders |
Encompasses therapeutic applications |
Demonstrating sufficient efficacy could be critical |
| Claim 15 |
Synthesis process |
Could prevent patent infringement on synthesis methods |
Validity depends on novelty and inventive step |
Conclusion
RE41065 offers a robust patent positioning for a class of substituted indole compounds with therapeutic potential in the CNS space. Its claims are strategically drafted to cover a broad chemical space, therapeutic uses, and synthesis methods. The patent landscape surrounding similar CNS modulators indicates a competitive environment, with key players like Janssen and Novartis.
The patent provides a secure exclusivity window until approximately 2028, with potential for extensions. Its scope necessitates vigilant freedom-to-operate assessments, especially considering existing patents on structurally related compounds.
Key Takeaways
- RE41065's scope encompasses specific substituted indole derivatives, method claims, and therapeutic applications, offering broad protection within its chemical class.
- The patent landscape in CNS drugs shows significant activity; competitors hold similar patents with overlapping claims, requiring careful legal monitoring.
- Patent strength derives from the specific substitutions claimed, synthesis methods, and demonstrated therapeutic efficacy.
- Companies developing similar compounds must evaluate potential infringement risks and consider designing around these claims or challenging the patent’s validity through prior art.
- The patent remains valuable until 2028, with potential for extension due to patent term adjustments, maintaining Eli Lilly’s market exclusivity in this therapeutic space.
FAQs
Q1: What is the primary chemical innovation claimed in RE41065?
A1: The patent claims specific substituted indole compounds with particular functional groups at designated positions, optimized for CNS activity.
Q2: Does RE41065 cover all indole derivatives for CNS applications?
A2: No, it specifically covers compounds with the defined substitutions and synthesis methods outlined in the claims, not all indole derivatives broadly.
Q3: How does RE41065 compare to similar patents in the CNS space?
A3: It appears broader in its chemical scope than some competitors’ narrow structural claims but is structurally limited compared to unrelated chemical classes.
Q4: Can a company develop compounds similar to those in RE41065 without infringing?
A4: Yes, if the compounds differ significantly in structure or substitutions outside the scope of the claims, freedom to operate may exist, but legal counsel should perform a detailed analysis.
Q5: What are the key factors influencing the patent’s enforceability?
A5: Claim novelty, inventive step, proper claim scope, and absence of prior art that discloses similar compounds or methods are critical factors.
References
[1] USPTO Patent Grant RE41065, 2012
[2] Eli Lilly Patent Portfolio, 2008–present
[3] Related Patent Families and PubMed Literature on Indole CNS Drugs
